NCT02252380View on ClinicalTrials.gov

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

NAActive, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Movement DisordersEssential TremorHolmes TremorParkinson's DiseaseWilson's DiseaseHuntington's DiseaseDystoniaTardive DyskinesiaOrofacial Dyskinesias
Interventions
DEVICE

Transcranial ExAblate System

MR Guided Focused Ultrasound

Trial Locations (2)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5T 2S8

Toronto Western Hospital, Toronto

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
lead

InSightec

INDUSTRY

NCT02252380 - ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders | Biotech Hunter | Biotech Hunter